加载中
Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (donor-derived) stem cells as specialized carriers for anti-tumor agents. This technology is being advanced to address a range of oncological conditions, including aggressive brain tumors (high-grade gliomas) and other solid malignancies. Calidi's proprietary cell-based delivery systems are expertly designed to safeguard, amplify, and boost the therapeutic effects of oncolytic viruses. This strategic delivery method aims to achieve superior treatment efficacy and enhance patient safety. The company's clinical pipeline features two primary candidates: NeuroNova, which employs allogeneic neural stem cells loaded with an oncolytic adenovirus specifically for the treatment of high-grade gliomas; and SuperNova, which utilizes allogeneic adipose-derived mesenchymal stem cells to deliver the tumor-selective CAL1 oncolytic vaccinia virus for advanced metastatic solid tumors. Established in 2014, Calidi Biotherapeutics operates out of San Diego, California.
收盘时
US$0.8999
−US$0.05 · -5.26%
盘后
US$0.88
−US$0.0199 · -2.21%
10月13日 16:11 ET
盘中时间采用ET。市场数据可能有所延迟。
Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (donor-derived) stem cells as specialized carriers for anti-tumor agents. This technology is being advanced to address a range of oncological conditions, including aggressive brain tumors (high-grade gliomas) and other solid malignancies. Calidi's proprietary cell-based delivery systems are expertly designed to safeguard, amplify, and boost the therapeutic effects of oncolytic viruses. This strategic delivery method aims to achieve superior treatment efficacy and enhance patient safety. The company's clinical pipeline features two primary candidates: NeuroNova, which employs allogeneic neural stem cells loaded with an oncolytic adenovirus specifically for the treatment of high-grade gliomas; and SuperNova, which utilizes allogeneic adipose-derived mesenchymal stem cells to deliver the tumor-selective CAL1 oncolytic vaccinia virus for advanced metastatic solid tumors. Established in 2014, Calidi Biotherapeutics operates out of San Diego, California.
日内区间
当前US$0.8999
52周区间
当前US$0.8999
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
44
合理估值
情绪
48
多空交织
风险
74
高风险
动量
17
强势下行
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (donor-derived) stem cells as specialized carriers for anti-tumor agents. This technology is being advanced to address a range of oncological conditions, including aggressive brain tumors (high-grade gliomas) and other solid malignancies. Calidi's proprietary cell-based delivery systems are expertly designed to safeguard, amplify, and boost the therapeutic effects of oncolytic viruses. This strategic delivery method aims to achieve superior treatment efficacy and enhance patient safety. The company's clinical pipeline features two primary candidates: NeuroNova, which employs allogeneic neural stem cells loaded with an oncolytic adenovirus specifically for the treatment of high-grade gliomas; and SuperNova, which utilizes allogeneic adipose-derived mesenchymal stem cells to deliver the tumor-selective CAL1 oncolytic vaccinia virus for advanced metastatic solid tumors. Established in 2014, Calidi Biotherapeutics operates out of San Diego, California.
日内区间
当前US$0.8999
52周区间
当前US$0.8999
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | — | — | 4.5万 USD | 44.9万 USD |
| 销货成本 | 165.1万 USD | — | 125.6万 USD | 27.4万 USD | 9.4万 USD |
| 毛利 | −165.1万 USD | — | −125.6万 USD | −22.9万 USD | 35.5万 USD |
| 研究与开发 | 973.7万 USD | 887.8万 USD | 1300.8万 USD | 725.7万 USD | 467.4万 USD |
| 销售、一般及管理费用 | 1050.3万 USD | 1289.8万 USD | 1598.4万 USD | 1564.2万 USD | 616.3万 USD |
| 营业费用 | 1858.9万 USD | 2177.6万 USD | 2773.6万 USD | 2289.9万 USD | 1083.7万 USD |
| 利息支出 | 20.7万 USD | 93.3万 USD | 374.9万 USD | 15.8万 USD | 61.4万 USD |
| 折旧和摊销 | 165.1万 USD | 153.5万 USD | 125.6万 USD | 25.3万 USD | 15.3万 USD |
| 营业利润 | −2024万 USD | −2177.6万 USD | −2899.2万 USD | −2312.8万 USD | −1048.2万 USD |
| 净利润 | −1990.6万 USD | −2214.3万 USD | −2921.6万 USD | −2542.7万 USD | −1093.3万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$5.50
上涨空间 511.18%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2026年7月31日 | 1:16 | — | — |
股票拆分 | 2025年8月5日 | 1:12 | — | — |
股票拆分 | 2024年7月15日 | 1:10 | — | — |
已生效 2026年7月31日
1:16
已生效 2025年8月5日
1:12
已生效 2024年7月15日
1:10
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
